IV Oxytocin

Phase 3Small molecule

GSK

IV Oxytocin is one of 17 small molecule programs targeting Postpartum Hemorrhage. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postpartum HemorrhageActive, not recruiting

Postpartum HemorrhagePhase 3

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Postpartum Hemorrhage

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Approved

24 2

Pitocin

RRetrophin

Approved

21 3

Cyklokapron

AAmring

Approved

17 4

Folvite

Eli Lilly

Approved

1 5

Syntocinon

SShana McCormack, MD

Approved

1 6

Syntometrine

NNorth Bristol NHS Trust

Approved

1 7

Pabal

AACADIA Pharmaceuticals Inc.

Preclinical

17 8

Circadin

NNeurim Pharmaceuticals Ltd.

IV Oxytocin

1 10

Fibrinogen Concentrate

GGold Coast Hospital and Health Service

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Postpartum Hemorrhage

NCT05245227

Clinical

Trials by Indication[1]

Pregnant Women1 trial

Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women

Terminated· GSK logo

GSK·Phase 1·NCT02999100·31 enrolled

Postpartum Hemorrhage1 trial

Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

Recruiting·SStony Brook University·Phase 3·NCT05245227·1,358 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IV Oxytocin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV Oxytocin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV Oxytocin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

IV Oxytocin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Pregnant Women1 trial

Postpartum Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News